 |
MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results
May 4, 2012
|
15.1 KB |
|
| |
MOUNTAIN VIEW, Calif., May 4, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the first quarter ended March 31, 2012.
The net loss for the first quarter ended March 31, 2012 was $17.8 million, compared to a net loss of $16.0 million during the same period in 2011. The net loss for the firs...
|
|
MAP Pharmaceuticals to Present at Upcoming Investor Conferences
May 1, 2012
|
7.4 KB |
|
| |
MOUNTAIN VIEW, Calif., May 1, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following investor conferences in May 2012:
Deutsche Bank 37th Annual Healthcare ConferenceTuesday, May 8, at 8:40 a.m. ET in Boston
Bank of America Merrill Lynch 2012 Healthcare Conferen...
|
|
MAP Pharmaceuticals Provides Update on LEVADEX® Program
Apr 12, 2012
|
8.7 KB |
|
| |
MOUNTAIN VIEW, Calif., April 12, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today provided an update on LEVADEX®, the Company's investigational orally inhaled drug for the potential acute treatment of migraine in adults.
The Company submitted a request to the U.S. Food and Drug Administration (FDA) for a meeting ...
|
|
MAP Pharmaceuticals Reports 2011 Fourth Quarter and Year End Financial Results
Mar 29, 2012
|
19.4 KB |
|
| |
MOUNTAIN VIEW, Calif., March 29, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the fourth quarter and year ended December 31, 2011.
The net loss for the fourth quarter ended December 31, 2011 was $13.8 million, compared to a net loss of $13.9 million during the same period in 2010. The net lo...
|
|
MAP Pharmaceuticals Receives Complete Response Letter from FDA for LEVADEX® (dihydroergotamine) NDA
Mar 26, 2012
|
10.1 KB |
|
| |
MOUNTAIN VIEW, Calif., March 26, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the United States Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for LEVADEX® (dihydroergotamine) inhalation aerosol.
In the Complete Response letter, the FDA re...
|
|
MAP Pharmaceuticals Issued Additional U.S. Patent for Methods of Achieving Rapid Treatment of Migraine Based Upon Pharmacokinetic Profile
Feb 23, 2012
|
8.3 KB |
|
| |
MOUNTAIN VIEW, Calif., Feb. 23, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the United States Patent and Trademark Office (USPTO) issued to the Company U.S. Patent No. 8,119,639, titled "Method of Therapeutic Administration of DHE to Enable Rapid Relief of Migraine while Minimizing Side Effect Profile." The p...
|
|
MAP Pharmaceuticals to Present at Upcoming Investor Conferences
Feb 8, 2012
|
7.3 KB |
|
| |
MOUNTAIN VIEW, Calif., Feb. 8, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following investor conferences in February 2012:
Leerink Swann 2012 Global Healthcare ConferenceThursday, February 16, at 11:30 a.m. ET in New York
2012 Citi Global Healthcare Conference...
|
|
MAP Pharmaceuticals Appoints W. James O'Shea to Board of Directors
Jan 17, 2012
|
9.3 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan. 17, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of W. James O'Shea to its Board of Directors. Mr. O'Shea brings to the Board 35 years of healthcare industry experience in product commercialization and operations.
"We are privileged to welcome Jim to our Board of Di...
|
|
MAP Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Jan 4, 2012
|
7.3 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan. 4, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the 30th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2012 at 10:00 a.m. PT in San Francisco.
A live webcast of the presentation will be available on the Investor Relations sectio...
|
|
MAP Pharmaceuticals Reports Third Quarter of 2011 Financial Results
Nov 8, 2011
|
16.1 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov. 8, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the third quarter ended September 30, 2011.
Net income for the three months ended September 30, 2011 was $11.2 million, compared to a net loss of $14.2 million during the same period in 2010. Net income for the first...
|
|
MAP Pharmaceuticals to Present at Upcoming Investor Conferences
Nov 3, 2011
|
8.0 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov. 3, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following investor conferences in November 2011:
Credit Suisse 2011 Healthcare ConferenceThursday, November 10, at 4:00 p.m. MT in Phoenix
Lazard Capital Markets 8th Annual Healthcare Conference...
|
|
MAP Pharmaceuticals to Present at Upcoming Investor Conferences
Sep 6, 2011
|
7.5 KB |
|
| |
MOUNTAIN VIEW, Calif., Sept. 6, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following investor conferences in September:
Stifel Nicolaus Healthcare ConferenceThursday, September 8, at 2:05 p.m. ET in Boston
UBS Global Life Sciences ConferenceWednesday, September 21, at...
|
|
MAP Pharmaceuticals Issued U.S. Patent for Methods of Achieving Rapid Relief of Migraine and Minimizing Side Effects Based Upon Pharmacokinetic Profile
Aug 11, 2011
|
9.8 KB |
|
| |
MOUNTAIN VIEW, Calif., Aug. 11, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the United States Patent and Trademark Office (USPTO) issued to the Company U.S. Patent No. 7,994,197, titled "Method of Therapeutic Administration of DHE to Enable Rapid Relief of Migraine while Minimizing Side Effect Profile." The pa...
|
|
MAP Pharmaceuticals to Present at Upcoming Investor Conference
Aug 11, 2011
|
7.2 KB |
|
| |
MOUNTAIN VIEW, Calif., Aug. 11, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the 2011 Wedbush Life Sciences: Management Access Conference on Tuesday, August 16, at 8:35 a.m. ET in New York.
A live webcast of the event will be available on the Investor Relations section of MAP ...
|
|
MAP Pharmaceuticals Appoints Frederick H. Graff Vice President, Commercial Operations
Aug 9, 2011
|
10.1 KB |
|
| |
MOUNTAIN VIEW, Calif., Aug. 9, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of Frederick H. Graff to the newly created position of Vice President, Commercial Operations.
Mr. Graff brings to MAP Pharmaceuticals more than 25 years of experience in commercial sales and marketing of pharmaceutical pro...
|
|
MAP Pharmaceuticals Reports Second Quarter of 2011 Financial Results
Aug 4, 2011
|
18.4 KB |
|
| |
MOUNTAIN VIEW, Calif., Aug. 4, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the second quarter ended June 30, 2011.
The net loss for the three months ended June 30, 2011 was $8.6 million compared to $12.5 million during the same period in 2010. The net income for the first six months of 2011...
|
|
MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX®
Aug 2, 2011
|
11.5 KB |
|
| |
MOUNTAIN VIEW, Calif., Aug. 2, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that its New Drug Application (NDA) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults has been accepted for filing by the U.S. Food and Drug Administration (FDA), with a goal date of March...
|
|
MAP Pharmaceuticals to Present Data on LEVADEX® at the 15th Congress of the International Headache Society
Jun 23, 2011
|
12.5 KB |
|
| |
MOUNTAIN VIEW, Calif., June 23, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that LEVADEX® orally inhaled migraine drug will be featured in four poster presentations, including one late-breaker presentation, at the 15th Congress of the International Headache Society (IHC) in Berlin, Germany on June 23-26, 2011....
|
|
MAP Pharmaceuticals to Present Data on LEVADEX® at the 53rd Annual Scientific Meeting of the American Headache Society
Jun 2, 2011
|
13.1 KB |
|
| |
MOUNTAIN VIEW, Calif., June 2, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present safety data on LEVADEX® orally inhaled migraine drug at the 53rd Annual Scientific Meeting of the American Headache Society (AHS) in Washington, DC, June 2-5, 2011. LEVADEX is an investigational acute drug ...
|
|
MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug
May 26, 2011
|
11.4 KB |
|
| |
MOUNTAIN VIEW, Calif., May 26, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults. According to the National Head...
|
|
|
